| Biosensors International Group, Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120116502 | SURFACE TEXTURED IMPLANTS - Devices and methods for controlling the flaking of coating fragments from medical implants and improving the delivery of therapeutic agents from such coatings are described. | 05-10-2012 |
| 20120046736 | SURFACE TEXTURED IMPLANTS - Devices and methods for controlling the flaking of coating fragments from medical implants and improving the delivery of therapeutic agents from such coatings are described. | 02-23-2012 |
| 20110160835 | INDIRECT-RELEASE ELECTROLYTIC IMPLANT DELIVERY SYSTEMS - Medical devices and methods for delivery or implantation of prostheses within hollow body organs and vessels or other luminal anatomy are disclosed. The subject technologies may be used in the treatment of atherosclerosis in stenting procedures or be used in variety of other procedures. The systems may employ a self expanding stent restrained by one or more members released by an electrolytically erodable latch. Such release means do not connect directly to the implant, though one or more portions may contact it. | 06-30-2011 |
| 20110123704 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD FOR TREATING RESTENOSIS - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating. | 05-26-2011 |
| 20110106236 | Temporal Intraluminal Stent, Methods of Making and Using - A biodegradable polymer stent with radiopacity and a method of making and using a stent with enhanced mechanical strength and/or controlled degradation for use in a bodily lumen is described. | 05-05-2011 |
| 20100262230 | Automated Coating Apparatus and Method - An automated apparatus and method for coating medical devices such as an intravascular stent, are disclosed in the method, a 2-D image of a stent is processed to determine (1) paths along the stent skeletal elements by which a stent secured to a rotating support element can be traversed by a dispenser head whose relative motion with respect to the support element is along the support-element axis, such that some or all of the stent skeletal elements will be traversed (2) the relative speeds of the dispenser head and support element as the dispenser head travels along the paths, and (3), and positions of the dispenser head with respect to a centerline of the stent elements as the dispenser head travels along such paths The rotational speed of the support and relative linear speed of the dispenser are controlled to achieve the desired coating thickness and coating coverage on the upper surfaces, and optionally, the side surfaces, of the stent elements | 10-14-2010 |
| 20100114303 | Surface Textured Implants - Devices and methods for controlling the flaking of coating fragments from medical implants and improving the delivery of therapeutic agents from such coatings are described. | 05-06-2010 |
| 20100094408 | Drug-Delivery Endovascular Stent and Method for Treating Restenosis - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns. | 04-15-2010 |
